VM Pharma
ActiveSummary
VM Pharma has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €242,551 and a net result of -€17,906. Equity is growing by about 13% per year across the filed financial years. Its solvency ranks better than 61% of 22,080 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
04-08
NBB filing
Annual accounts filed
financial year 2025 · micro format · 4 days late
2025
31-12
Financial
Weakest financial yearnet -€17,906
Net result drops to -€17,906, the lowest in the series.
24-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
17-06
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
29-06
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Highest result from 2020 to 2025net €92,490 ▲167%
Operating result €127,142, net result €92,490, both a record.
31-12
Financial
Equity above €200,000equity €216,574 ▲74.5%
A profit in every financial year since 2020 builds equity to €216,574.
22-06
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Equity above €100,000equity €124,125 ▲38.7%
A profit in every financial year since 2020 builds equity to €124,125.
27-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 27 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.